QpiAI Announces Dawn of Quantum Era in India With 25 Qubit Quantum Computer
16.4.2025 06:30:00 CEST | Business Wire | Press Release
QpiAI, a leader in quantum computing and generative AI, announced its First Quantum computer launch code named QpiAIIndusQuantum Computer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415961497/en/
QpiAI Gen-1 25 qubit Quantum computer Indus, picture from QpiAI Bangalore centre with CEO Dr Nagendra Nagaraja (Left) and VP of Quantum hardware Dr Manjunath R V (Right).
Dr Nagendra Nagaraja, CEO and Founder of QpiAI, said, "We are excited about our roadmap to commercialize quantum computers, leveraging large-scale qubit integration and logical qubits. The T1 and T2 times for our current 25-Qubit Indus Quantum Computer are 30 μs and 25 μs, respectively, characterized by our in-house developed quantum control electronics cluster, and are expected to increase to 100 μs soon. Furthermore, with our patented qubit architecture, we expect to reach a T1 time of 1 ms in early 2026. With single-qubit gate fidelity of 99.7% and two-qubit gate fidelity of 96%, supporting all native gate sets, our system is interfaced with QpiAI quantum software SDKs for application development. We will soon be expanding to 64-qubit quantum computers. We will have rich partnerships with fellow component suppliers, large pharma and chemical companies, data center players, and hyperscalers to commercialize quantum computing. Our key IP lies in using an AI-based agentic system to manufacture qubits and fine-tune them to obtain desired fidelity, error correction, and noise levels, where the Agentic AI system in our datacenter works in a closed loop with the quantum computer."
Department of Science and Technology (DST) who is also shareholder of QpiAI via NQM (National Quantum Mission) announced QpiAI Indus Quantum computer in a LinkedIn post
QpiAI Quantum and AI Full-Stack Vertical Integration
QpiAI has developed full-stack quantum computing technology vertically integrating AI and Quantum computing systems combining AI, quantum computers, algorithms, software, and applications. The Gen-1 QpiAI system is built with efficient Quantum-HPC integration with a colocated HPC datacenter for high-throughput and low-latency computing. The QpiAI quantum applications stack combines AI-driven quantum compilation with application-specific architectures for maximizing hybrid quantum-classical performance. QpiAI Quantum software platforms and products, including QpiAI-Logistics, QpiAI-Opt, QpiAI-ML, QpiAI-Pharma, and QpiAI-Matter, are targeted for core quantum applications in logistics, finance, material discovery, and pharma industries.
QpiAI Quantum QPU Technology
QpiAI quantum computers use superconducting qubits and roadmap to experiment with CMOS-based spin qubits in future models. The current generation of qubits is based on various architectures of superconducting qubits design. QpiAI NISQ (Noisy Intermediate-Scale Quantum) qubits and QpiAI FTQC (Fault-tolerant Quantum Computing) qubits are based on QpiAI proprietary qubit architecture named QpiAI Qubits. Transmon qubits are stabilized and error-corrected based on the surface codes with various distances. For higher reliability in fault-tolerant computing, QpiAI FTQC Qubits are error-corrected using Q-LDPC codes with new architectures invented by QpiAI to ensure high performance and low error rates.
Quantum computing today faces limited scalability and reliability challenges due to errors from decoherence, noise, and gate inaccuracies, impacting readiness for industrial applications. To address these, QpiAI is advancing error mitigation on NISQ devices with built-in Surface code schemes, and implementing Q-LDPC codes within our fault-tolerant roadmap. We aim to create scalable, reliable quantum systems capable of supporting complex, high-impact applications.
AI Technology
QpiAI has built advanced next generation generative AI and agentic AI systems that can autonomously navigate complex scenarios and build emergent intelligence through agent-based modeling. Our optimized data-to-intelligence stack and high-performance infrastructure enables modeling and automation at unprecedented scales, while ensuring a seamless transition to quantum-based modeling in the future with the optimal combination of bits, qubits, and neurons.
About QpiAI
QpiAI (https://www.qpiai.tech) is a Bangalore based deep-tech startup pioneering the convergence of Artificial Intelligence and Quantum Computing to solve some of the world’s most complex industrial and scientific challenges. QpiAI’s vertically integrated stack enables seamless innovation across hardware, software, and applications. The portfolio includes QpiAI-Explorer, an education platform; QpiAI-Quantum, offering SDKs, compilers, and simulators for quantum development; QpiAI-Opt, a powerful optimization engine for scientific and industrial use cases; QpiAI-Logistics, for route planning and supply chain optimization; QpiAI-Pharma, designed for drug discovery and protein-ligand modeling; QpiAI-Pro, a generative AI development suite; and QpiAI Agent-Hive, enabling intelligent agentic AI workflows.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415961497/en/
Contacts
Contact email: info@qpiai.tech
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom